Drugs & Targets CHMP adopts positive opinion of zolbetuximab for advanced gastric and gastroesophageal junction cancer August 02, 2024Vol.50 No.31
Drugs & Targets Expanded access program opens in the U.S. for TLX101-CDx, Telix’s investigational glioma imaging agent August 02, 2024Vol.50 No.31
Drugs & Targets Labcorp, Ultima Genomics collaborate to advance whole genome sequencing applications and oncology testing capabilities August 02, 2024Vol.50 No.31
Drugs & Targets FDA accepts Telix’s NDA for prostate cancer imaging agent July 26, 2024Vol.50 No.30
Drugs & Targets FDA clears IND for Zymeworks’ antibody drug conjugate ZW191 July 26, 2024Vol.50 No.30
Drugs & Targets EMA validates application for BMS’s Opdivo + Yervoy for unresectable or advanced HCC July 26, 2024Vol.50 No.30
Drugs & Targets EMA accepts MAA for GSK’s Blenrep combinations for R/R MM July 26, 2024Vol.50 No.30
Drugs & Targets FDA grants Fast Track designation to 225Ac-FL-020 radiopharmaceutical for mCRPC July 12, 2024Vol.50 No.28
Drugs & Targets Boehringer Ingelheim, OSE Immunotherapeutics collaborate to advance clinical development of SIRP immuno-oncology program July 12, 2024Vol.50 No.28
Drugs & Targets Wistar, Accelerated Biosciences collaborate to develop immune cell therapies July 12, 2024Vol.50 No.28
